High Point Advisor Group LLC Halozyme Therapeutics, Inc. Transaction History
High Point Advisor Group LLC
- $1.75 Billion
- Q4 2024
A detailed history of High Point Advisor Group LLC transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, High Point Advisor Group LLC holds 5,982 shares of HALO stock, worth $381,711. This represents 0.02% of its overall portfolio holdings.
Number of Shares
5,982
Previous 5,944
0.64%
Holding current value
$381,711
Previous $340,000
16.18%
% of portfolio
0.02%
Previous 0.02%
Shares
2 transactions
Others Institutions Holding HALO
# of Institutions
552Shares Held
124MCall Options Held
668KPut Options Held
259K-
Black Rock Inc. New York, NY17.6MShares$1.12 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$848 Million0.01% of portfolio
-
State Street Corp Boston, MA7.18MShares$458 Million0.01% of portfolio
-
Snyder Capital Management L P San Francisco, CA4.17MShares$266 Million4.34% of portfolio
-
Bank Of America Corp Charlotte, NC3.45MShares$220 Million0.01% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.89B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...